# Biotech Daily Digest — 2025-10-18

**16 items from 2 sources**

## Summary by Source

- Endpoints News: 7 items
- Fierce Biotech: 9 items


## Endpoints News

- **[#ESMO25: Padcev-Keytruda combo extends survival in Phase 3 bladder cancer trial](https://endpoints.news/esmo25-padcev-keytruda-combo-extends-survival-in-phase-3-bladder-cancer-trial/)**  
  _Sat, 18 Oct 2025 14:30:51 +0000_  
  BERLIN — Two years ago, Padcev and Keytruda got a standing ovation at ESMO for confirmatory data in locally advanced or metastatic bladder cancer. And now, there are new Phase 3 data ...

- **[#ESMO25: Enhertu could move into 'curative' breast cancer setting on the strength of Phase 3 data](https://endpoints.news/esmo25-enhertu-could-move-into-curative-breast-cancer-setting-on-the-strength-of-phase-3-data/)**  
  _Sat, 18 Oct 2025 14:30:08 +0000_  
  BERLIN – AstraZeneca and Daiichi Sankyo unveiled details of a late-stage success for their blockbuster drug Enhertu in an early form of breast cancer ahead of surgery where the companies believe it could help cure ...

- **[#ESMO25: Celcuity details Phase 3 breast cancer win as it works on FDA submission](https://endpoints.news/esmo25-celcuity-details-phase-3-breast-cancer-win-as-it-works-on-fda-submission/)**  
  _Sat, 18 Oct 2025 08:30:30 +0000_  
  BERLIN — Celcuity said Saturday it saw “paradigm-shifting results” in a subset of its Phase 3 breast cancer trial and plans to complete a new drug application by the end of the year.

 The biotech  ...

- **[#ESMO25: Roche’s SERD is the first shown to work in non-mutant breast cancer patients](https://endpoints.news/esmo25-roches-serd-is-the-first-shown-to-work-in-non-mutant-breast-cancer-patients/)**  
  _Sat, 18 Oct 2025 05:00:27 +0000_  
  Roche’s breast cancer pill giredestrant is the first member of its class — the selective estrogen receptor degraders, or SERDs — to prove itself effective in patients who do not have a mutated version of the receptor ...

- **[#ESMO25: Grail’s cancer test better at spotting real cases as FDA filing nears](https://endpoints.news/grails-cancer-test-better-at-spotting-real-cases-as-fda-filing-nears/)**  
  _Fri, 17 Oct 2025 22:05:05 +0000_  
  Grail’s blood test got better at telling when a positive result actually means cancer based on study findings, potentially strengthening the company’s case for a wider rollout, though questions remain.

 Results from the company’s PATHFINDER ...

- **[#AAO25: Roche’s eye drug yields one hit, one miss in pivotal trials](https://endpoints.news/aao25-roches-eye-drug-yields-one-hit-one-miss-in-pivotal-trials/)**  
  _Fri, 17 Oct 2025 20:20:59 +0000_  
  Roche’s investigational therapy for a disorder that can cause blindness failed in one of its two pivotal trials, and it is not clear whether its results will be good enough for approval.

 The identical trials ...

- **[CHMP rejects Sanofi’s Rezurock over clinical data issues, but recommends Wayrilz](https://endpoints.news/chmp-rejects-sanofis-rezurock-over-clinical-data-issues-but-recommends-wayrilz/)**  
  _Fri, 17 Oct 2025 14:44:13 +0000_  
  The European Medicines Agency's human medicines committee (CHMP) rejected Sanofi’s Rezurock after a clinical trial was cut short because it showed no benefits in patients.

 Rezurock, which is available in the US for the treatment ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/esmo-roche-wants-oral-serd-benefit-all-comers-unveils-phase-3-breast-cancer-data" hreflang="en">ESMO: Roche wants oral SERD to benefit ‘all comers,’ unveils phase 3 breast cancer data</a>](https://www.fiercebiotech.com/biotech/esmo-roche-wants-oral-serd-benefit-all-comers-unveils-phase-3-breast-cancer-data)**  
  _Oct 17, 2025 10:39am_  
  Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% in a specific cohort of a phase 3 trial.

- **[<a href="https://www.fiercebiotech.com/biotech/xoma-and-lava-cool-buyout-lowering-both-cash-offer-and-closing-conditions" hreflang="en">Xoma and Lava buyout cools with lower cash offer and closing conditions</a>](https://www.fiercebiotech.com/biotech/xoma-and-lava-cool-buyout-lowering-both-cash-offer-and-closing-conditions)**  
  _Oct 17, 2025 2:38pm_  
  Xoma Royalty and Lava Therapeutics are turning the temperature down, dropping both the cash per share offer and closing cash conditions for an acquisition inked back in August.

- **[<a href="https://www.fiercebiotech.com/biotech/esmo-evaxion-keytruda-vaccine-combo-hits-75-melanoma-response-rate-after-2-years" hreflang="en">ESMO: Evaxion hopes cancer vax data attract partner after cash crunch forces smaller phase 2 trial</a>](https://www.fiercebiotech.com/biotech/esmo-evaxion-keytruda-vaccine-combo-hits-75-melanoma-response-rate-after-2-years)**  
  _Oct 17, 2025 11:08am_  
  Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring a 75% objective response rate (ORR) in patients with advanced melanoma after two years. But the trial enrolled far fewer patients than originally planned and did not evaluate its primary endpoin…

- **[<a href="https://www.fiercebiotech.com/biotech/esmo-pfizer-sees-year-long-weight-gain-cancer-patients-wasting-condition" hreflang="en">ESMO: Pfizer sees year-long weight gain in cancer patients with wasting condition</a>](https://www.fiercebiotech.com/biotech/esmo-pfizer-sees-year-long-weight-gain-cancer-patients-wasting-condition)**  
  _Oct 17, 2025 11:09am_  
  For the second year running, Pfizer has arrived at the European Society for Medical Oncology (ESMO) conference armed with data showing its one-time heart failure hopeful ponsegromab can treat a wasting syndrome.

- **[<a href="https://www.fiercebiotech.com/biotech/licensing-galore-roche-ties-hansoh-adcs-rani-rounds-out-week-chugai-drug-delivery-pact" hreflang="en">Licensing galore: Roche ties up with Hansoh on ADCs as Rani rounds out week with Chugai pact</a>](https://www.fiercebiotech.com/biotech/licensing-galore-roche-ties-hansoh-adcs-rani-rounds-out-week-chugai-drug-delivery-pact)**  
  _Oct 17, 2025 9:58am_  
  Hansoh has announced a deal with Roche worth up to $1.45 billion biobucks to grant the Swiss drugmaker a global license to develop, manufacture and sell its experimental ADC. At the same time, Rani has secured an agreement worth up to $1.09 billion to wed its drug delivery tech with Chugai's antibody assets in rare di…

- **[<a href="https://www.fiercebiotech.com/biotech/astellas-walks-away-gene-therapy-pact-taysha-pivotal-trial-launch" hreflang="en">Astellas walks away from gene therapy pact with Taysha before pivotal trial launch</a>](https://www.fiercebiotech.com/biotech/astellas-walks-away-gene-therapy-pact-taysha-pivotal-trial-launch)**  
  _Oct 17, 2025 10:24am_  
  For the second time, Astellas is walking away from Taysha Gene Therapies, this time choosing not to license the biotech’s adeno-associated-virus-based therapy designed to treat a rare neurodevelopmental condition.

- **[<a href="https://www.fiercebiotech.com/biotech/i-mab-undergoes-makeover-new-name-strategy-asset-and-hong-kong-ipo-plans" hreflang="en">I-Mab undergoes makeover, with new name, strategy, asset and Hong Kong IPO plans</a>](https://www.fiercebiotech.com/biotech/i-mab-undergoes-makeover-new-name-strategy-asset-and-hong-kong-ipo-plans)**  
  _Oct 17, 2025 10:17am_  
  Less than two years after laying out plans to divest its China operations and become a U.S.-focused biotech, I-Mab Biopharma is re-staking its claim in the Asia-Pacific region.

- **[<a href="https://www.fiercebiotech.com/pharma/big-pharma-bets-big-mash" hreflang="en">Big Pharma bets big on MASH with a new combo playbook</a>](https://www.fiercebiotech.com/pharma/big-pharma-bets-big-mash)**  
  _Oct 14, 2025 1:30pm_  
  After Rezdiffra’s approval and Wegovy’s label expansion, the race is on in metabolic dysfunction-associated steatohepatitis. M&A deals totaling more than $10 billion in recent months show major pharma players still see sizable opportunity in the field.

- **[<a href="https://www.fiercebiotech.com/biotech/we-can-have-tiktok-why-cant-we-have-drugs-nkarta-ceo-hastings-urges-us-drop-china-tariffs" hreflang="en">'We can have TikTok. Why can’t we have drugs?': Nkarta CEO Paul Hastings warns against China biotech penalties</a>](https://www.fiercebiotech.com/biotech/we-can-have-tiktok-why-cant-we-have-drugs-nkarta-ceo-hastings-urges-us-drop-china-tariffs)**  
  _Oct 15, 2025 4:49pm_  
  As geopolitical tensions rise, Nkarta CEO Paul Hastings is urging the U.S. government not to impose restrictions on Chinese scientific collaboration and refocus on what matters most: the patient.
